Anti-viral drug treatment: Dynamics of resistance in free virus and infected cell populations

Journal of Theoretical Biology

Volumn 184, Issue 2, 1997, Pages 203-217

  Nowak, Martin A ^a   Bonhoeffer, Sebastian ^a   Shaw, George M ^b   May, Robert M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NEVIRAPINE;

ARTICLE; CASE REPORT; DRUG RESISTANCE; HALF LIFE TIME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; PROVIRUS; VIRUS INFECTION; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0031581661     PISSN: 00225193     EISSN: None     Source Type: Journal    
DOI: 10.1006/jtbi.1996.0307     Document Type: Article

References (45)

1. ANDERSON, R. M. & MAY, R. M. (1991). Infectious Diseases of Humans. Oxford: Oxford University Press.
2. BOUCHER, C. A., TERSMETTE, M., LANGE, J. M., KELLAM, P., DE GOEDE, R. E., MULDER, J. W., et al. (1990) Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 336(8715), 585-90.
3. BOUCHER, C. A., LANGE, J. M., MIEDEMA, F. F., WEVERLING, G. J., KOOT, M., MULDER, J. W., et al. (1992) HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 6, 1259-1264.
4. BOUCHER, C. A., O'SULLIVAN, E., MULDER, J. W., RAMAUTARSING, C., KELLAM, P., DARBY, et al. (1992). Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J. Infect. Dis. 165(1), 105-110.
5. COFFIN, J. M. (1995). HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267, 483-489.
6. DEACON, N. J., TSYKIN, A., SOLOMON, A., SMITH, K., LUDFORD-MENTING, M., HOOKER, D. J., et al. (1995). Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270, 988-991.
7. DE BOER, R. J. & BOERLIJST, M. C. (1994). Diversity and virulence thresholds in AIDS. Proc. Natl. Acad. Sci. USA 94, 544-548.
8. DE BOER, R. J. & BOUCHER, C. A. B. (1996) Anti-CD4 therapy for AIDs suggested by mathematical models. Proc. R. Soc. Lond. B, 263, 899-905.
9. DE JONG, M. D., VEENSTRA, J., STILIANAKIS, N. I., SCHUURMAN, R., LANGE, J. M. A., DE BOER, R. J. & BOUCHER, C. A. B. (1996). Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of HIV-1 RNA load suppression by zidovudine. Proc. Nat. Acad. Sci. USA, in press.
10. ERON, J. J., BENOIT, S. L., JEMSEK, J., MACARTHUR, R. D., SANTANA, J., QUINN, J. B. et al. (1995) Treatment with lamivudine, zidovudine or both in HIV-positive patients with 200 to 500 CD4 cells per cubic millimeter. New Eng. J. Med. 333, 1662-1669.
11. FROST, S. D. W. & MCLEAN, A. R. (1994) Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS 8, 323-332.
12. HERZ, A. V. M., BONHOEFFER, S., ANDERSON, R. M., MAY, R. M. & NOWAK, M. A. (1996). Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. Proc. Natl. Acad. Sci. USA 93, 7247-7251.
13. HO, D. D., TOYOSHIMA, T., MO, H., KEMPF D. J., NORBECK, D., CHEN, C. M., et al. (1994). Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68, 2016-2020.
14. HO, D. D., NEUMANN, A. U., PERELSON, A. S., CHEN, W., LEONARD, J. M. & MARKOWITZ, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995 Jan 12; 373(6510): 123-126.
15. HO, D. D. (1996). Viral counts count in HIV infection. Science 272, 1124-1125.
16. KLENERMAN, P., PHILLIPS, R. E., RINALDO, C. R., MCMICHAEL, A. J. & NOWAK, M. A. (1996). CTL-mediated lysis and viral turnover in HIV-1 infection, submitted.
17. KIRSCHNER, D. E. & WEBB, G. F. (1996). Effects of drug resistance on monotherapy treatment of HIV infection. J. theor. Biol., in press.
18. LARDER, B. A., DARBY, G. & RICHMAN, D. D. (1989). HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731-1734.
19. LARDER, B. A. & KEMP, S. D. (1989). Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246, 1155-1158.
20. LARDER, B. A., KELLAM, P. & KEMP, S. D. (1993). Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 365, 451-453.
21. LARDER, B. A., KEMP, S. D. & HARRIGAN, P. R. (1995). Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269, 696-699.
22. LOVEDAY, C., KAYE, S., TENANT-FLOWERS, M., SEMPLE, M., AYLIFFE, U., WELLER, I. V. & TEDDER R. S. (1995). HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 345, 820-824.
23. MARKOWITZ, M., MO, H., KEMPF, D. J., NORBECK, D. W., BHAT, T. N., ERICKSON, J. W. & HO, D. D. (1995). Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69, 701-706.
24. MCLEAN, A. R., EMERY, V. C., WEBSTER, A. & GRIFFITHS, P. D. (1991). Population dynamics of HIV within an individual after treatment with zidovudine. AIDS 5, 485-489.
25. MCLEAN, A. R. & NOWAK, M. A. (1992). Interactions between HIV and other pathogens. J. theor. Biol. 155, 69-86.
26. MCLEAN, A. R. & NOWAK, M. A. (1992). Competition between zidovudine sensitive and resistant strains of HIV. AIDS 6, 71-79.
27. MCLEAN, A. R. & FROST, S. D. W. (1995). Zidovudine and HIV: mathematical models of within-host population dynamics. Reviews in Medical Virology 5, 141-147.
28. MELLORS, J. W., RINALDO, C. R., GUPTA, P., WHITE, R. M., TODD, J. A. & KINGSLEY, L. A. (1996). Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167-1170.
29. MOHRI, H., SINGH, M. K., CHING, W. T. & HO, D. D. (1993). Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc. Natl. Acad. Sci. USA 90, 25-29.
30. NOWAK, M. A., MAY, R. M. & ANDERSON, R. M. (1990). The evolutionary dynamics of HIV quasispecies and the development of immunodeficiency disease. AIDS 4, 1095-1103.
31. NOWAK, M. A., ANDERSON, R. M., MCLEAN, A. R., WOLFS, T., GOUDSMIT, J. & MAY, R. M. (1991). Antigenic diversity thresholds and the development of AIDS. Science 254, 963-969.
32. NOWAK, M. A., MAY, R. M., PHILLIPS, R. E., ROWLAND-JONES, S., LALLOO, D. G., MCADAM, S., et al. (1995). Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 375, 606-611.
33. NOWAK, M. A. & MCMICHAEL, A. J. (1995). How HIV defeats the immune system. Scientific American 273, 58-65. August 1995.
34. NOWAK, M. A., BONHOEFFER, S., LOVEDAY, C., BALFE, P., SEMPLE, M., KAYE, S., et al. (1995). HIV-1 dynamics: Results confirmed. Nature 375, 193.
35. NOWAK, M. A. & BANGHAM, C. R. M. (1996). Population dynamics of immune responses to persistent viruses. Science 272, 74-79.
36. PERELSON, A. S., NEUMANN, A. U., MARKOWITZ, M., LEONARD, J. M. & HO, D. D. (1996). HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 271, 1582-1585.
37. RICHMAN, D. D. (1990). Zidovudine resistance of human immunodeficiency virus. Rev. Infect. Dis. 12 Suppl. 5, S507-510.
38. RICHMAN, D. D., HAVLIR, D., CORBEIL, J., LOONEY, D., IGNACIO, C., SPECTOR, S. A., et al. (1994). Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68, 1660-1666.
39. RICHMAN, D. D. (1994). Drug resistance in viruses. Trends Microbiol. 2, 401-407.
40. SCHUURMAN, R., NIJHUIS, M., VAN LEEUWEN, R., SCHIPPER, P., DE JONG, D., COLLIS, P., et al. (1995). Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171, 1411-1419.
41. SIMMONDS, P., ZHANG, L. Q., MCOMISH, F., BALFE, P., LUDLAM, C. A. & BROWN, A. J. (1991). Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis. J. Virol. 65(11), 6266-6276.
42. STASZEWSKI, S. (1995). Zidovudine and lamivudine: results of phase III studies. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10 Suppl. 1, S57.
43. ST. CLAIR, M. H., MARTIN, J. L., TUDOR-WILLIAMS, G., BACH, M. C., VAVRO, C. L., KING, D. M., et al. (1991). Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253, 1557-1559.
44. WEI, X., GHOSH, S. K., TAYLOR, M. E., JOHNSON, V. A., EMINI, E. A., DEUTSCH, P., et al. (1995). Viral dynamics in HIV-1 infection. Nature 373, 117-122.
45. WEIN, L. M., ZENIOS, S. & NOWAK, M. A. (1997). Dynamic multidrug therapies for HIV: a control theoretic approach. J. theor. Biol., in press.